// App-Quantinova.ai

BSH2020‐EP‐064 : Improved outcomes in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib during earlier lines of therapy

Researchers

Presenter

  • T. Munir

Principal Investigators

  • A. Tedeschi

  • P. Hillmen

  • J. Woyach

  • J. C. Byrd

  • P. Ghia

  • S. P. Mulligan

  • S. Dai

  • C. Amaya-Chanaga

  • J. P. Dean

  • S. M. O'Brien

  • P. M. Barr

Medical Centers

  • Haematology, St James's University Hospital, Leeds

  • Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Experimental Haematology, Leeds Teaching Hospitals, Leeds, UK

  • Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

  • Division of Experimental Oncology,Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,Milano,Italien

  • School of Psychology, The University of Sydney, Sydney, Australia

  • Biostatistics

  • CSL Medical Affairs

  • Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale

  • Hematology/Oncology, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine

  • Department of Medicine- Hematology/Oncology, University of Massachusetts, Worcester, MA

Locations

  • United Kingdom

  • Italy

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

Drug/Treatment

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01722487

  • NCT01578707

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved